Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDS00428
Target NameGamma-aminobutyric acid receptor subunit gamma-2    
Type of TargetSuccessful target    
Drug Potency against TargetZK-93423IC50 = 1 nM[1]
CGS-9895IC50 = 100 nM[2]
3-demethoxy-3-L-fucopyranosylaminothiocolchicineIC50 = 10500 nM[3]
3-demethoxy-3-D-mannopyranosylaminothiocolchicineIC50 = 11300 nM[3]
1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-oneIC50 = 1140 nM[4]
AMENTOFLAVONEIC50 = 14.9 nM[5]
1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-oneIC50 = 16000 nM[6]
3-demethoxy-3D-glucopyranosylaminothiocolchicineIC50 = 18000 nM[3]
3,3-Diisopropyl-dihydro-furan-2-oneIC50 = 220 nM[4]
3-Ethyl-3-methyl-dihydro-furan-2-oneIC50 = 2280 nM[4]
GAMMA-AMINO-BUTANOIC ACIDIC50 = 24 nM[3]
3-Ethyl-3-isopropyl-dihydro-furan-2-oneIC50 = 240 nM[4]
(4R)-4-ammoniopentanoateIC50 = 2500 nM[7]
(2E,4S)-4-ammoniopent-2-enoateIC50 = 2600 nM[7]
(4S)-4-ammoniopentanoateIC50 = 2900 nM[7]
3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-oneIC50 = 300 nM[6]
3-tert-Butyl-3-ethyl-dihydro-furan-2-oneIC50 = 310 nM[4]
3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-oneIC50 = 3100 nM[6]
THIOCOLCHICOSIDEIC50 = 3400 nM[3]
1-Methyl-5-oxa-spiro[2.4]heptan-4-oneIC50 = 3410 nM[4]
6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-oneIC50 = 360 nM[4]
3-Isothiocyanato-9H-beta-carbolineIC50 = 4 nM[8]
CGS-13767IC50 = 4 nM[9]
3-amino-3-demethoxythiocolchicineIC50 = 5400 nM[3]
5-[(1S)-1-ammonioethyl]isoxazol-3-olateIC50 = 5800 nM[7]
6-Methyl-2-oxa-spiro[4.4]nonan-1-oneIC50 = 680 nM[4]
3-demethoxy-3-D-xylopyranosylaminothiocolchicineIC50 = 7000 nM[3]
ELTANOLONEIC50 = 71 nM[10]
ALLOPREGNANOLONEIC50 = 74 nM[10]
3-Isopropyl-3-methyl-dihydro-furan-2-oneIC50 = 740 nM[4]
3,3-Diethyl-dihydro-furan-2-oneIC50 = 750 nM[4]
4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-olIC50 = 78 nM[11]
6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-oneIC50 = 780 nM[4]
ridine-5-carboxylic acid ethyl esterIC50 = 79 nM[12]
2-Oxa-spiro[4.4]nonan-1-oneIC50 = 810 nM[4]
5-[(1R)-1-ammonioethyl]isoxazol-3-olateIC50 = 9500 nM[7]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicineIC50 = 9700 nM[3]
6-benzyl-3-propylaminocarbonyl-4-quinoloneKi = 0.048 nM[13]
6-benzyl-3-propoxycarbonyl-4-quinoloneKi = 0.17 nM[13]
RO-194603Ki = 0.2 nM[14]
TPA-023Ki = 0.2 nM[15]
6-ethyl-3-propylaminocarbonyl-4-quinoloneKi = 0.26 nM[13]
L-655708;NCGC00025115-02Ki = 0.4 nM[16]
3-butylaminocarbonyl-6-ethyl-4-quinoloneKi = 0.54 nM[13]
U-89267Ki = 0.65 nM[17]
CGS-17867AKi = 0.77 nM[18]
2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinolineKi = 1 nM[19]
3-Methyl-9H-beta-carbolineKi = 1.1 nM[20]
(beta-CCE)9H-beta-Carboline-3-carboxylic acidKi = 1.2 nM[21]
RO-147437Ki = 1.3 nM[14]
6-benzyl-3-ethoxycarbonyl-4-quinoloneKi = 1.4 nM[13]
U-78875Ki = 1.6 nM[22]
2-Thiophen-2-yl-3H-imidazo[4,5-c]quinolineKi = 1.7 nM[19]
6-ethyl-3-propoxycarbonyl-4-quinoloneKi = 1.8 nM[13]
3-butoxy-9H-pyrido[3,4-b]indoleKi = 1000 nM[23]
ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylateKi = 1000 nM[23]
3-ethoxy-9H-pyrido[3,4-b]indoleKi = 1000 nM[23]
beta-Carboline-3-carboxylic acid t-butyl esterKi = 1000 nM[23]
3-propoxy-9H-pyrido[3,4-b]indoleKi = 1000 nM[23]
3-(benzyloxy)-9H-pyrido[3,4-b]indoleKi = 10000 nM[23]
3-isobutoxy-9H-pyrido[3,4-b]indoleKi = 10000 nM[23]
3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indoleKi = 10000 nM[23]
3-(isopentyloxy)-9H-pyrido[3,4-b]indoleKi = 10000 nM[23]
2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-oneKi = 1120 nM[24]
N-butyl-2-(1H-indol-3-yl)-2-oxoacetamideKi = 1175 nM[25]
6-Nitro-2-(3-nitro-phenyl)-chromen-4-oneKi = 12 nM[26]
3-butoxycarbonyl-6-ethyl-4-quinoloneKi = 13 nM[13]
PNU-91571Ki = 13.2 nM[27]
4-(2-aminoethyl)-1,2,5-oxadiazol-3-olKi = 13000 nM[28]
Ro-4882224Ki = 14 nM[29]
GNF-PF-3645Ki = 15 nM[13]
Ro-154513Ki = 15 nM[17]
6-bromo-3-ethoxycarbonyl-4-quinoloneKi = 16 nM[13]
CI-218872Ki = 160 nM[20]
3-ethoxycarbonyl-6-propyl-4-quinoloneKi = 17 nM[13]
6-Nitro-2-(4-nitro-phenyl)-chromen-4-oneKi = 17000 nM[26]
5-(piperidin-4-yl)isothiazol-3-olKi = 1870 nM[30]
3-cyclopentoxycarbonyl-6-ethyl-4-quinoloneKi = 19 nM[13]
CGS-9896Ki = 2.4 nM[24]
GNF-PF-4421Ki = 20 nM[13]
3-carboxy-6-ethyl-4-quinoloneKi = 208 nM[13]
6-ethyl-3-i-propoxycarbonyl-4-quinoloneKi = 214 nM[13]
sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylateKi = 216 nM[23]
N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamideKi = 2160 nM[31]
4-Phenyl-5-piperidin-4-yl-isoxazol-3-olKi = 220 nM[32]
4-Methyl-5-(4-piperidyl)isothiazol-3-olKi = 2200 nM[30]
3-Ethoxy-9H-beta-carbolineKi = 25.1 nM[33]
6-ethyl-3-(3-pentoxycarbonyl)-4-quinoloneKi = 2600 nM[13]
Ethyl 9H-pyrido[3,4-b]indole-3-carboxylateKi = 2700 nM[23]
6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinoloneKi = 28 nM[13]
6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinoloneKi = 28 nM[13]
N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamideKi = 31.3 nM[25]
1-(4-chlorophenyl)-4-phenyl-1H-imidazoleKi = 3290 nM[24]
4-benzyl-5-(4-piperidyl)isothiazol-3-olKi = 331 nM[30]
N-benzyl-2-(1H-indol-3-yl)-2-oxoacetamideKi = 346 nM[25]
6-ethyl-3-pentoxycarbonyl-4-quinoloneKi = 35 nM[13]
4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-olKi = 36 nM[32]
2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamideKi = 380 nM[21]
4-Benzyl-5-piperidin-4-yl-isoxazol-3-olKi = 3800 nM[32]
6-bromo-3-ethoxycarbonyl-2-methyl-4-quinoloneKi = 4200 nM[13]
5-(4-piperidyl)-4-propylisothiazol-3-olKi = 440 nM[30]
4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazoleKi = 4480 nM[24]
RO-145974Ki = 45 nM[14]
RY-066Ki = 48 nM[34]
Ro-151310Ki = 5.4 nM[14]
RO-145975Ki = 53 nM[14]
3-butoxycarbonyl-4-quinoloneKi = 54 nM[13]
N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamideKi = 65 nM[25]
3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinoloneKi = 6580 nM[13]
GABAZINEKi = 74 nM[30]
GABAZINEKi = 74 nM[32]
3-ethoxycarbonyl-4-quinoloneKi = 78 nM[13]
Ro-4938581Ki = 80 nM[29]
4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-olKi = 820 nM[32]
5-Piperidin-4-yl-isoxazol-3-olKi = 9100 nM[32]
6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinoloneKi = 92 nM[13]
N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamideKi = 943 nM[25]
Ref 1J Med Chem. 1990 Mar;33(3):1062-9.Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester. To Reference
Ref 2J Med Chem. 1987 Oct;30(10):1737-42.1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. To Reference
Ref 3J Med Chem. 2006 Sep 7;49(18):5571-7.3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. To Reference
Ref 4J Med Chem. 1994 Jan 21;37(2):275-86.Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant alpha,alpha-disubstituted gamma-butyrolactones. To Reference
Ref 5Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. To Reference
Ref 6J Med Chem. 1988 Jan;31(1):1-3.Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ligands. To Reference
Ref 7J Med Chem. 1981 Dec;24(12):1377-83.gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. To Reference
Ref 8J Med Chem. 1990 Sep;33(9):2343-57.Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. To Reference
Ref 9J Med Chem. 1991 Jan;34(1):281-90.Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. To Reference
Ref 10J Med Chem. 2005 Apr 21;48(8):3051-9.Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (3alpha,5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one. To Reference
Ref 11J Med Chem. 2010 Apr 22;53(8):3417-21.Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relationships. To Reference
Ref 12J Med Chem. 1989 Dec;32(12):2561-73.Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. To Reference
Ref 13J Med Chem. 2006 Apr 20;49(8):2526-33.4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore modeling. To Reference
Ref 14J Med Chem. 1993 Apr 16;36(8):1001-6.Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepine receptors. To Reference
Ref 15J Med Chem. 2005 Nov 17;48(23):7089-92.7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. To Reference
Ref 16J Med Chem. 2004 Mar 25;47(7):1807-22.3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. To Reference
Ref 17J Med Chem. 1994 Mar 18;37(6):758-68.Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. To Reference
Ref 18Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. To Reference
Ref 19J Med Chem. 1996 Jul 5;39(14):2844-51.Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. To Reference
Ref 20J Med Chem. 1994 Dec 23;37(26):4576-80.Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. To Reference
Ref 21J Med Chem. 1992 Jun 12;35(12):2214-20.Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. To Reference
Ref 22J Med Chem. 1996 Sep 13;39(19):3820-36.3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepine receptor complex. To Reference
Ref 23Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. Epub 2010 Sep 29.Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse. To Reference
Ref 24J Med Chem. 2006 Mar 23;49(6):1855-66.Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. To Reference
Ref 25J Med Chem. 2007 Apr 5;50(7):1627-34. Epub 2007 Mar 3.Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands. To Reference
Ref 26Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995) To Reference
Ref 27J Med Chem. 1996 Nov 8;39(23):4654-66.High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracyclic imidazoquinoxalines. To Reference
Ref 28J Med Chem. 2006 Jul 13;49(14):4442-6.Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of gamma-aminobutyric acid (GABA) related compounds. To Reference
Ref 29Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. Epub 2009 Aug 15.The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. To Reference
Ref 30J Med Chem. 2006 Feb 23;49(4):1388-96.Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. To Reference
Ref 31J Med Chem. 2001 Jul 5;44(14):2286-97.Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular modeling analysis of the structure-activity relationships. To Reference
Ref 32J Med Chem. 2005 Jan 27;48(2):427-39.Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. To Reference
Ref 33J Med Chem. 1998 Jul 2;41(14):2537-52.Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors. To Reference
Ref 34J Med Chem. 1998 Oct 8;41(21):4130-42.Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via comparative molecular field analysis. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543